Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Assertio Therapeutics Inc (ASRT)
NASDAQ:ASRT
Holding ASRT?
Track your performance easily
ASRT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.73 - $1.80
Previous Close$0.85
Volume4.49M
Average Volume (3M)533.39K
Market Cap
$96.29M
Enterprise Value$31.39M
Total Cash (Recent Filing)$88.38M
Total Debt (Recent Filing)$38.73M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Nov 11, 2024EPS Estimate
-$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.11
Shares Outstanding95,335,629
10 Day Avg. Volume775,558
30 Day Avg. Volume533,395
Standard Deviation0.25
R-Squared0.00145
Alpha0.00226
Financial Highlights & Ratios
Price to Book (P/B)0.61
Price to Sales (P/S)0.61
Price to Cash Flow (P/CF)2.70
P/FCF Ratio2.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.24
Enterprise Value/Gross Profit0.25
Enterprise Value/Ebitda-0.13
Forecast
1Y Price Target
$3.00Price Target Upside252.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Assertio Therapeutics News
PremiumCompany Announcements
Assertio Therapeutics’ Governance and Shareholder Decisions UpdateBulls Say, Bears Say
Bulls Say
Growth PotentialWith an established CEO, a strong balance sheet, and cash-generating assets, the Company's poised to return to growth.
Market PositionRolvedon has experienced six consecutive quarters of demand growth and has biologic exclusivity until 2034, providing a long revenue/cash runway.
ValuationASRT shares trade at a 75% discount to peers on a revenue basis, offering an opportunity for investors.
Bears Say
Market CompetitionThe launch by Zydus of a generic was an unfortunate occurrence for the Company’s self-described unicorn product.
Product PerformanceIndocin revenues continuing to diminish, and mixed performances from the other portfolio products, acquisitions will be key to sustaining long-term growth.
Revenue ImpactThe principal source of variance in 2024 revenue is likely to be the evolution of the genericization of Indocin, formerly Assertio's most significant revenue driver.
---
Ownership Overview
2.01% Insiders
8.21% Mutual Funds
0.53% Other Institutional Investors
83.40% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ASRT FAQ
What was Assertio Therapeutics Inc’s price range in the past 12 months?
Assertio Therapeutics Inc lowest stock price was $0.73 and its highest was $1.80 in the past 12 months.
What is Assertio Therapeutics Inc’s market cap?
Currently, no data Available
When is Assertio Therapeutics Inc’s upcoming earnings report date?
Assertio Therapeutics Inc’s upcoming earnings report date is Nov 11, 2024 which is tomorrow.
How were Assertio Therapeutics Inc’s earnings last quarter?
Assertio Therapeutics Inc released its earnings results on Aug 07, 2024. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of -$0.032 by -$0.008.
Is Assertio Therapeutics Inc overvalued?
According to Wall Street analysts Assertio Therapeutics Inc’s price is currently Undervalued.
Does Assertio Therapeutics Inc pay dividends?
Assertio Therapeutics Inc does not currently pay dividends.
What is Assertio Therapeutics Inc’s EPS estimate?
Assertio Therapeutics Inc’s EPS estimate is -$0.05.
How many shares outstanding does Assertio Therapeutics Inc have?
Assertio Therapeutics Inc has 95,335,630 shares outstanding.
What happened to Assertio Therapeutics Inc’s price movement after its last earnings report?
Assertio Therapeutics Inc reported an EPS of -$0.04 in its last earnings report, missing expectations of -$0.032. Following the earnings report the stock price went down -12.195%.
Which hedge fund is a major shareholder of Assertio Therapeutics Inc?
Among the largest hedge funds holding Assertio Therapeutics Inc’s share is Royce & Associates LLC. It holds Assertio Therapeutics Inc’s shares valued at 94K.
---
Assertio Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (252.94% Upside)
$3.00 (252.94% Upside)
Blogger Sentiment
Bullish
ASRT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 25.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.09%
12-Months-Change
Fundamentals
Return on Equity
-178.62%
Trailing 12-Months
Asset Growth
-31.03%
Trailing 12-Months
Company Description
Assertio Therapeutics Inc
Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.
---
ASRT Earnings Call
Q2 2024
0:00 / 0:00
---
ASRT Stock 12 Month Forecast
Average Price Target
$3.00
▲(252.94% Upside)
Technical Analysis
Aldeyra Therapeutics
―
TuHURA Biosciences
―
Relmada Therapeutics
―
Aileron Therapeutics
―
Best Analysts Covering ASRT
1 Year
1 Year Success Rate
7/30 ratings generated profit
1 Year Average Return
-27.75%
initiated a buy rating 6 months ago
Copying Scott Henry's trades and holding each position for 1 Year would result in 23.33% of your transactions generating a profit, with an average return of -27.75% per trade.
---